rAhc

evi fo

DIS

(52-13 ) 6831 75

52 6831 75

).D.hP(** ).D.M( *+ ).D.M(*** ).D.hP(**

5 II : .

. 54 . :

) A .

. ( )B (

. . . 32/01 81/8 :

. .

: .

:

.

. 28 -04 (

- : + () * moc.oohay@iradyehjahz :liamE

( ) ** *** 58/21/9: 58/8/72: 58/7/4: (

ri.DIS.www

rAhc

evi fo

DIS

62 6831 75

.

.

.

.

-5 2 .(1)

.(2)

. (3-8)

.

-5

.(9-11)

0/500 .(21)

.(831)

1

.

54 (212) ) .

( 4831 2831)

.

03 5

02 01

.

.

:

. .

-

.

ri.DIS.www

rAhc

evi fo

DIS

72 6831 75

. M4K CMPH

42 .

006 .

04 06

. muK .

4 .

.

. (8) 1

1 .

)

( .

)A

)B ( . (

.

:

) ( ) . 6 (

. .

01

3

( )

.

:

4=3/5-5) ( 1=8/1-9/5 2=6/6-8 3=5/1-6/5

3=051-471 4=571-002) ( 1= 001-421 2=521-941 3=511 -931 4=041-561) (. 1=56-98 2=09-411

3-6 9 -21 6-9

. (41) . tset-T

ri.DIS.www

rAhc

evi fo

DIS

82 6831 75

7 54

7 22/8 3/3 .

( 18/6) 13 ( 81/4) ( 18/6) 13

. 91 . 32/01 81/8

. B 91 A

. 1

. ( =P0/100)

( ) (. 510.0=P)

B

(. =P0/720) BA

2 . (=P0/100)

.

:1

eulav-P

eulav-P

0/246 43/12 931/47 33/19 741/8 0/0000 53/33731/98 63/82 351/65 0/0000

0/166 73/6801/24 93/47311/ 72 0/100

93/33 501/85 73/94 811/16 0/0000

0/354 2/80 7/12 2/14 6/27 0/80 2/82 7/55 2/717/81 0/70

)mc(

:2

eulav-P

()

0/295 1 21 25/2 6 05 11 74/8 6 05

0/613 2 31 65/5 5 14/7 01 34/5 7 85/3 0/844 3 21 45/5 6 64/2 01 54/5 7 35/8 0/844 4 21 45/5 6 64/2 01 54/5 7 35/8 0/346 5 21 45/5 6 65/5 01 34/5 5 45/5 0/936 6 21 54/5 6 45/5

01 45 5 65

ri.DIS.www

rAhc

evi fo

DIS

92 6831 75

. .

. " 1

( 65 45/5) - 5 .

II -

.

1 gm .(71-1251)

.

6 .(P=0/000) .(101)

.(1)

.

. 432

. "

6 3 42 21

.(2)

.

(21115)

.

..

ri.DIS.www

Arch

ive of

SID

57 1386 30

.

1. Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight

and hair count in men with androgenetic

alopecia after treatment with finasteride,

1 mg, dialy. J. Am. Acad. Dermatol. 2002;

46(4): 517-23.

2. Dunlop F. Androgenetic alopecia in men and women: An overview of cause

and treatment. 2005. Availible from:

www.folicle.com\ section 2\2. html.

3. Oslen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EA,

et al. A randomized clinical trial of 5%

topical minoxidil versus 2% topical

minoxidil and placebo in the treatment of

androgenetic alopecia in men. J. Am.

Acad. Dermatol. 2002; 47(3): 377-85.

4. Hugo Perez BS. Ketokonazole as an adjuct of finasteride in the treatment of

androgenetic alopecia in men. Medical

Hypotheses. 2004; 62:112-5.

5. Sintova A, Srafimovich S, Gilhar A. New topical antiandrogenic formulation

can stimulate hair growth in human bald

scalp grafted onto mice. Int. J. Pharm.

2000; 194(1): 125-34.

6. Vexiau P, Chaspoux C, Boudou P, Jouanique C, Feit J, Hardy N, et al.

Effects of minoxidil 2% versus

cyproterone acetatec treatment on female

androgenetic alopecia: A controlled, 12-

month randomized trial. Br. J. Dermatol.

2002; 146(6): 992-9.

7. Burkhart CG, Burkhart G. 5alpha reductase and finasteride in pattern

alopecia and acne. J. Drug Dermatol.

2004: 240-3.

8. Hamilton JB. Drug category. 2003. Avalable frome: www. emedicine.com/

derm/topic21.htm.

9. Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with

androgenetic alopecia (Male pattern hair

loss). J. Am. Acad. Dermatol. 2003; 8(1):

20-23.

. . . . . . .

. . 1383 . 1 . 97-106.

11. Lucas KJ.Finasteride creame in hirsutism. End. Practice. 2001; 7(1): 5-10.

12. Mazzarella F, Loconsole F, Cammisa A, Mastrolonardo M, Vena GA. Topical

www.SID.ir

Arch

ive of

SID

57 1386 31

finasteride in the treatment of androgenetic

alopecia. Preliminary evaluation after a

16-month therapy course. J. Dermatol.

Treat. 1997; 8: 189-92.

13. Altomare G, Capella G. Depression circumstantialy related to the

administration for androgenetic alopecia.

J. Dermatol. 2002; 29(10): 665-9.

. . .

. 1385. 35 :9-15.

15. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL. The effect

of Finasteride, a 5-reductase inhibitor,

on scalp skin testosterone and

dihydrotestosterone concentration in

patients with male pattern baldness. Clin.

End. Metab. 1994; 79: 703-6.

16. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al.

Finasteride in the treatment of men with

androgenetic alopecia. Finasteride Male

Pattern Hair Loss Study Group. J. Am.

Acad. Dermatol. 1998 Oct; 39(4 Pt 1):

578-89.

17. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E,

Shupack J, Stough D, et al. Clinical dose

ranging studies with finasteride, a type 2

5alpha-reductase inhibitor, in men with

male pattern hair loss. J. Am. Acad.

Dermatol. 1999 Oct; 41(4): 555-63.

www.SID.ir